Treatment of pulmonary arterial hypertension: The role analogs

Respiratory Medicine

105, 818-827

DOI: 10.1016/j.rmed.2010.12.018

Citation Report

#	Article	IF	Citations
1	Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. BMC Pulmonary Medicine, 2011, 11, 56.	2.0	16
2	Adult Congenital Heart Disease and Pulmonary Arterial Hypertension: The Texas Adult Congenital Heart Program Experience. Postgraduate Medicine, 2011, 123, 32-45.	2.0	4
3	A new epoprostenol formulation for the treatment of pulmonary arterial hypertension. American Journal of Health-System Pharmacy, 2012, 69, 1389-1393.	1.0	13
5	Smooth Muscle Myosin Inhibition: A Novel Therapeutic Approach for Pulmonary Hypertension. PLoS ONE, 2012, 7, e36302.	2.5	5
6	Portopulmonary hypertension: An update. Liver Transplantation, 2012, 18, 881-891.	2.4	90
7	Ozone induces synthesis of systemic prostacyclin by cyclooxygenase-2 dependent mechanism in vivo. Biochemical Pharmacology, 2012, 83, 506-513.	4.4	26
8	Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist. Biochemical Pharmacology, 2012, 84, 68-75.	4.4	124
9	Synergistic effects of prostacyclin analogs and phosphodiesterase inhibitors on cyclic adenosine 3â€²,5â€² monophosphate accumulation and adenosine 3â€²5â€² triphosphate release from human erythrocytes. Experimental Biology and Medicine, 2013, 238, 1069-1074.	2.4	18
10	Pulmonary arterial hypertension in pregnant women. Therapeutic Advances in Respiratory Disease, 2013, 7, 51-63.	2.6	22
11	Scleroderma lung disease. European Respiratory Review, 2013, 22, 6-19.	7.1	230
12	Targeted Delivery of Genes to Endothelial Cells and Cell- and Gene-Based Therapy in Pulmonary Vascular Diseases. , 2013, 3, 1749-1779.		15
13	The Use of Lobelia in the Treatment of Asthma and Respiratory Illness. Journal of Restorative Medicine, 2013, 2, 94-100.	0.6	4
14	Epoprostenol (VeletriÂ®, CaripulÂ®): A Review of Its Use in Patients with Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2014, 14, 463-470.	2.2	13
15	Reactive Oxygen Species and Antioxidants in Pulmonary Hypertension and Right Heart Failure. , 2014, , 1671-1687.		0
17	Management of Crashing Patients with Pulmonary Hypertension. Emergency Medicine Clinics of North America, 2015, 33, 623-643.	1.2	3
18	Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. European Respiratory Review, 2015, 24, 630-641.	7.1	78
19	Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension. Journal of Cardiovascular Pharmacology, 2016, 67, 322-325.	1.9	12
20	Pharmacological treatment for Buerger's disease. The Cochrane Library, 2016, 3, CD011033.	2.8	13

#	Article	IF	Citations
21	Practical considerations for therapies targeting the prostacyclin pathway. European Respiratory Review, 2016, 25, 418-430.	7.1	33
22	Pharmacological treatment for Buerger's disease. , 2016, 2, CD011033.		27
23	Portopulmonary hypertension. Scandinavian Journal of Gastroenterology, 2016, 51, 795-806.	1.5	6
24	Selexipag: A Review in Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2017, 17, 73-80.	2.2	17
25	Endogenous PGI2 signaling through IP inhibits neutrophilic lung inflammation in LPS-induced acute lung injury mice model. Prostaglandins and Other Lipid Mediators, 2018, 136, 33-43.	1.9	11
26	Prostacyclins in Cardiac Surgery: Coming of Age. Seminars in Cardiothoracic and Vascular Anesthesia, 2018, 22, 306-323.	1.0	7
27	Prostanoid EP₄ agonist L-902,688 activates PPARÎ³ and attenuates pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L349-L359.	2.9	25
28	Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA). Orphanet Journal of Rare Diseases, 2018, 13, 220.	2.7	11
29	The Vascular Endothelium. , 2018, , 5-10.		2
30	Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension. Frontiers in Physiology, 2018, 9, 890.	2.8	23
31	EP4 Agonist L-902,688 Suppresses EndMT and Attenuates Right Ventricular Cardiac Fibrosis in Experimental Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2018, 19, 727.	4.1	22
32	Pharmacokinetics-Driven Optimization of 4(3H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. Journal of Medicinal Chemistry, 2019, 62, 4979-4990.	6.4	25
33	Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan. Journal of International Medical Research, 2019, 47, 2177-2186.	1.0	7
34	Urantide improves the structure and function of right ventricle as determined by echocardiography in monocrotaline-induced pulmonary hypertension rat model. Clinical Rheumatology, 2019, 38, 29-35.	2.2	11
35	Vascular Metabolic Mechanisms of Pulmonary Hypertension. Current Medical Science, 2020, 40, 444-454.	1.8	3
36	Pharmacological treatment for Buerger's disease. The Cochrane Library, 2020, 5, CD011033.	2.8	12
37	Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review. Dermatologic Therapy, 2021, 34, e14669.	1.7	12
38	Circulating miRNAs as Potential Marker for Pulmonary Hypertension. PLoS ONE, 2013, 8, e64396.	2.5	106

#	Article	IF	Citations
40	Successful Liver Transplant Complicated by Severe Portopulmonary Hypertension After an Initial Aborted Attempt: Case Report and Review of Treatment Options. Experimental and Clinical Transplantation, 2017, 15, 361-365.	0.5	0
41	Brain Natriuretic Peptide Response to Six-minute Walk Test in Pulmonary Arterial Hypertension. International Journal of Pulmonary & Respiratory Sciences, 2019, 4, .	0.1	0
42	Modulating the Pulmonary Circulation: Nitric Oxide and Beyond. , 2022, , 105-114.		1
43	Pulmonary hypertension: a woman's disease. Texas Heart Institute Journal, 2013, 40, 302-3.	0.3	2
44	The Prostaglandin Transporter: Eicosanoid Reuptake, Control of Signaling, and Development of High-Affinity Inhibitors as Drug Candidates. Transactions of the American Clinical and Climatological Association, 2015, 126, 248-57.	0.5	10
45	Antiplatelet effects of prostacyclin analogues: Which one to choose in case of thrombosis or bleeding?. Cardiology Journal, 2021, 28, 954-961.	1.2	5
46	Prostacyclin (PGI2) scaffolds in medicinal chemistry: current and emerging drugs. Medicinal Chemistry Research, 0, , .	2.4	0
47	Nanodeliovery based Chinese medicine's bioactive compounds for treatment of respiratory disorders. Pharmacological Research Modern Chinese Medicine, 2022, 5, 100180.	1.2	0
48	Portopulmonary Hypertension: A Review. Advances in Pulmonary Hypertension, 2022, 21, 123-129.	0.1	0
49	Identification of biomarkers related to copper metabolism in patients with pulmonary arterial hypertension. BMC Pulmonary Medicine, 2023, 23, .	2.0	3
50	Vascular and pulmonary effects of ibuprofen on neonatal lung development. Respiratory Research, 2023, 24, .	3.6	3
51	The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension. European Respiratory Journal, 2023, 62, 2300561.	6.7	1
52	The Emerging Therapeutic Role of Prostaglandin E2 Signaling in Pulmonary Hypertension. Metabolites, 2023, 13, 1152.	2.9	0